Prestige Management Fights Back Following Biosimilar Rejection

CEO And COO Buy Up nearly 140,000 Shares To ‘Reinforce Trust’

 
• By Dean Rudge

Prestige BioPharma’s top brass are looking to restore shareholder confidence following the surprise failure of their trastuzumab biosimilar before the EMA’s CHMP.

Singapore (Prasit Rodphan/Alamy Stock Photo)
Prestige is appealing the EMA's verdict • Source: Shutterstock (Alamy Stock Photo)

Prestige Biopharma’s senior management have put their money where their mouth is following the recent failure of the company’s trastuzumab biosimilar before the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products